Thelansis

Spinal Muscular Atrophy (SMA) Market Outlook Thelansis’s “Spinal Muscular Atrophy (SMA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Spinal Muscular Atrophy (SMA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

  Spinal Muscular Atrophy (SMA) Market Outlook Thelansis’s “Spinal Muscular Atrophy (SMA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Spinal Muscular Atrophy (SMA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is characterized by the degeneration of alpha motor neurons in the anterior horn cells of the spinal cord, leading to progressive weakness and wasting of proximal muscles and, in severe cases, paralysis. The clinical presentation of SMA varies from severe to mild. It is classified into three subtypes: type I (also known as Werdnig-Hoffman disease),...

 Spinal muscular atrophy (SMA) is characterised by degeneration of the alpha motor neurons of the anterior horn cells of the spinal cord, resulting in progressive proximal muscle weakness and atrophy and, in the most severe types, paralysis. The clinical phenotype of SMA is heterogeneous, ranging from severe to mild. It is classified into three subtypes: type I (also known as Werdnig Hoffmann disease), type II, and type III (also called Kugelberg Welander disease). ·        The estimated prevalence of spinal muscular atrophy (SMA) in the USA ranges between 9 to 10 cases per 100,000 population. However, the incidence cases range between 1.2 to 1.5 cases per 11,000 live birth population. Thelansis’s “Spinal Muscular Atrophy (SMA) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice,...

  Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Etiology- SMA types 0, 1, 2, 3, and 4 are inherited as autosomal recessive genetic disorders and are associated with abnormalities (mutations) in the SMN1 and SMA2 genes on chromosome 5 at chromosomal locus 5q11-q13. SMA1 is thought to be the primary disease-causing gene. Epidemiology- Spinal muscular atrophy affects 1 per 8,000 to 10,000 people worldwide. The competitive landscape of Spinal muscular atrophy (SMA) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Spinal muscular atrophy (SMA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment land...